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Oral Presentations 
fibric acid derivatives used as needed to control hyperlipidemia. 
The overall response rate was 68% (n=18), with 5 CR and 13 PR. 
Of the remaining patients, 6 failed to respond, 3 had progressive 
disease and 2 patients were not evaluable. Response by disease 
location included skin (n=17), lower GI (n=l), liver (n=l), mucosal 
(n=3), and ocular (n=2). 6/8 (75%) of patients with scleroderma 
responded. Overall, sirolimus was tolerated well, with mostly 
reversible adverse ffects which included: hypertriglyceridemia 
(22, 76%), hypereholesterolemia (8, 28%), hypertension (i6, 
55%), thrombocytopenia (11, 38%), and leukopenia (6, 21%). 
Fourteen (48%) patients remain alive, with 11 deaths occurring 
from progression of cGVHD. Overall smMval since sirolimus ini- 
tiation was 42%, (95% CI 23-61). Combination therapy with 
sirolituus and tacrolimus i  an active regimen for the treatment of 
steroid refractory cGVHD, particularly in patients with steroid- 
refractory scleroderma. Based on these preliminary findings, fur- 
ther investigation of sirolimus in combination with tacrolimus for 
the management of cGVHD is warranted. 
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DONOR PRETREATMENT WITH PROGENIPOIETIN-I PREVENTS 
ACUTE GRAFT-VERSUS-HOST DISEASE IN AN IL-IO DEPENDENT 
FASHION AND AUGMENTS THE GRAFT-VERSUS-LEUKEMIA EFFECT 
3dacDo,ald, K.P/; Rowe, IA~; Filipich, Cd; k~glply, J.K.:; Ferrava, 
ff.L.S; Hill, G.R. s 1. The QaeeJzslmzd hzstitute of Medical Resea~vh, 
Brisba~ze, QLD, AHs't~wlia; 2. Phavmacia, St Lo,is, MO; 3. U, iversity 
of Michigal~, dTz~ d 'bo'~; MI. 
We have studied the ability of stem cell grafts mobilised with the 
chimeric G-CSF and FLT-3 receptor agonist Progenipoietin-1 
(ProGP-1) to separate graft-versus-host disease (GVHD) and graft- 
versus-leukemia (GVL) in the well described B6 ~ B6D2F1 stem 
ceil transplant (SCT) nmdel. ProGP-1, G-CSF or control diluent 
was administered to donor B6 mice. ProGP 1 expanded all cell ine- 
ages in the spleen and blood with dramatic expansion of dendritic 
cells (DC) and granulocyte-nmnocyte lin ages (2-log increase). 
Transplant survival was 0%, 50% and 90% in recipients of control, 
G-CSF and ProGP-I treated allogeneic donor splenocytes respec- 
tively (P<0.0001). Donor pretreatment with ProGP-1 allowed a 2 to 
4-fold escalation in T cell dose over that possible with G-CSF. 
Donor CD4 T cells from allogeneic SCT recipients of ProGP 1 
splenocytes demonstrated ananergic response to host antigen (pro- 
liferation and cytokine) while CD8 T cell cytotoxicity to host anti 
gens remained intact. Neither CD1 lc hi DC nor "plasmacytoid" 
CDllc'I~m/B220 hi DC |roln ProGP-1 treated onor animals con- 
ferred protection from GVIID. Conversely, when equa] numbers of 
purified T cells from contro], G-CSF or ProGP-1 treated allogene- 
ic donors were added to allogeneic T-cell depleted control spleen, 
survival at day 60 was 0%, 15% and 90% respectively (P<0.0001). 
The improved survival in recipients of ProGP-1 T cells was associ- 
ated with reductions in systemic TNF0c generation (Control v 
ProGP-l: 227--82 v 35+14 pg/ml, P<0.01) and GVHD of the GI 
tract (senti-quantitative GVHD score: 19.5+2.1 v 9.5+0.4, P<0.01). 
Splenocytes from ProGP-1, but not control nor G-CSF treated ani- 
mals produced large amounts of IL-I0 to CpG. Furthermore, 
ProGP-1 expanded IL-lff/- splenocytes tailed to prevent GVI-ID 
relative to wild type (survival: 0% v 67%, P<0.001). In GVL experi- 
ments shown below, host type P815 was added to grafts on day 0 
and survival was monitored for 70 days after SCT. Recipients of 
ProGP-1 splenocytes containing either low or high T ceil doses rel 
ative to G-CSF had improved overall survival due to reduced 
GVtlD mortality and leukemia relapse (~P<0.05 v G-CSF). These 
data confirm that donor pretreatment with ProGP-1 prevents 
GVHD in an IL 10 and T cell dependent fashion and is superior to 
G-CSF in separating GVHD and GVL after allogeneic SCT. 
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APPLICATION OF IMMUNE-THERAPEUTIC INTERVENTIONS AFTER 
ALLOGENEIC STEM-CELL TRANSPLANTATION BASED ON MRD 
DETECTION WITH COMBINED MORPHOLOGICAL AND CYTOGENETIC 
ANALYSIS 
S,~imo,i, A. 1; Trakhte~brot, L. 2; Bielo~:ai, B.1; Re#hart, 3/i. 3; Rothmm~, 
R.2; Torel~, d.;; Rechavi, G.2; Nagler, dd 1. Bolle Jllavvow Tva71s'pla~l- 
tatio~z, Cha#n Sheba Medical Ce1~teT, el~Hashomer, Israel; 2. Hema- 
tology a,d Pediat'de Hemato-O,eology, Chah, Sheba 3Iedieal Ce~zteJ, 
Tel-Hashomer; 3. Bio View LtD, Nes-Zio~ea. 
Recurrent disease remains a major obstacle to cure after allo- 
geneic transplantation. Detection of MRD allows timely applica- 
tion of immune-therapeutic interventions such as early withdrawal 
of immunesuppression or DLI to those destined to relapse. We 
used a novel system (Duet-TM, BioView), which provides com- 
bined morphological and cytogenetic analysis on the same ceils 
(Leukemia 2000; 16:1413). Large numbers of cells are automati- 
cally scanned and their coordinates aved. MGG staining is 
removed and FISH is applied to the same slide. Small recipient- 
derived populations are targeted and their images relocated to 
identify their morphology. Patients (pts) are informative for Duet 
analysis if they have cytogenetic abnormalities or sex-mismatched 
donors. Thirty-five serial tests were performed in 31 leukemia pts. 
Results were retrospectively correlated with outcome. Four pts 
were counted twice due to different results at different ime- 
points. Duet detected minute recipient type populations (<5%) in 
28 tests. In ten tests recipient ceils were mostly blasts and in 18 
they were mature hematopoietie c lls (MHC). Seven of the ten pts 
with blasts relapsed, 3 had TRM before clinical relapse could be 
documented. Among the 18 pts with MHC morphology, one had 
early TRM and none of the others relapsed (P=0.002). Duet had 
increased sensitivity in detection of host population when com- 
pared with standard FISH. Duet specificity in predicting relapse 
was also superior to FISH. Seventy percent of those with recipient 
type blasts relapsed compared to 25% of those with any recipient 
population as detected by FISH with no specified morphology 
(p=0.05). We started applying this system prospectively for clinical 
decision-making. In two pts minute recipient blast-population 
(<1%) was detected 1-3 months post-transplant, hmnune-suppres- 
sion was rapidly tapered off. One pt developed GVHD 2-weeks 
later, when she had I5% blasts, and spontaneously re-entered sus- 
tained remission. The other pt progressed espite further inter- 
ventions. Identification of residual recipient-type cells as blasts 
predicts imminent relapse and these patients need additional ther- 
apy. YVhen residual recipient cells are MHC, pts can be followed 
with serial testing and need not be subjected to the hazards of 
additional therapy. 
HISTOCO M PATIBILITY/ALTERNATIVE STEM 
CELL SOURCES 
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INTERLEUKIN-IO AND TUMOUR NECROSIS FACTOR ALPHA HAPLO- 
TYPES PREDICT TRANSPLANT RELATED MORTALITY AFTER UNRE- 
LATED DONOR STEM CELL TRANSPLANTS 
L Hows, J.3/I.1; Keem .J.-; Defor, T.S; Bidwell, J.L.2; Davies, S.M.S; 
Bradley, B.Ad I. Divisiol~ of 7;nmz~'pla~ztatio~l ScieTwes, Depavtmellt of 
Cl&icfll Medici~e, Utzivevsity of Bristol, Bristol, Ulzited Kilzgdom; 
2. 3/Ioleczdar btl, munogelzetics, DepavtmeTzt of Pathology aJzd Microbiol- 
ogy, UMversity of Bristol, Bristol, Ulzited KiTzgdom; 3. DepalwzleJzt of 
Boise Marrow Tra~spla77tatioJz aJtd Clhdcal Resea'rch, U1ffvevsity of 
Mi~zlzesota, Mimzeapolis, 3 I~  
]'here is evidence that serum levels of tumour necrosis factor- 
alpha (TNF-a) and IL-10 influence the probability of transplant 
related mortality (TRM) and acute graft versus host disease after 
HLA identical sibling stem cell transplantation (SCT). Certain 
genetic polymorphisms of these cytokines may also correlate with 
outconae of HLA matched unrelated onor SCT. We have stud- 
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led the contribution of cyto!dne gene polymorphisms to TRM in 
182 consecutive unrelated onor transplants performed in a sin- 
gle center. Haplotypes forTNF and IL-I0 genes were construct- 
ed using estimated haplotype analysis. W~e then analysed hapln- 
type associations with transplant outcome, confirming our 
findings by multifactoriaI analysis. The TNF-d microsatellite d4 
allele was strongly linked to the TNF-a 1031 C and TNF a5 
alleles. The TNF d4/-1031C haplotype when present in both 
donor and recipient was significantly associated with high TRM, 
55% (43 - 67%) versus 21% (i2 - 30%) when absent from both, 
p= <0.01. The donor IL-10 haplotype R2- (IL-10G)-G-C-C was 
associated with increased risk of TRIM, 61% (43-79%) compared 
with 34% (25-43%), p=0.01. The R3- (IL IOG)-G-C-C haplo- 
type associated with decreased risk, 30% (I9-41%), compared 
with 53% (40-66%), p=0.01. This is the first demonstration that 
TNF-a and IL-10 polymorphisms independently influence TP~VI 
after unrelated onor SCT and emphasises the importance of 
analysing haplotypes rather than single polymorphic loci. We 
conclude that analysis of cytokine gene haplotypes could be used 
pre-transplant to identi .fy donors and recipients who carry a high 
or low risk of TRM. 
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MATURATION STAGE OF CORD BLOOD NATURAL KILLER CELLS 
Dural, AI. 1; Da/le, if~; ~agT~er, E/; Blagdm~, M. 1; Cha'mpagne, if.l; 
Champlwze, M/; Menezes, ff.e 1. Division of Hemato-OJ~colo©,, Hopi- 
tal Sainte-ffustine, Molztveal, QC, Canada; 2. Laboratory of 
Immmzovivolog~, Resea*vh Cente*; Hopital Sailzte-ffzlstiJle, ~loT~t'reaL 
OC Ca*2acla. 
Absence of killer-cell inmaunoglobulin-like receptor (KIR) trig- 
gering in donor NK cells decreases the rate of reIapse, rejection 
and GVHD and improves urvival in clinical haplo-identical 
hematopoietie transplantation. Like immature NK cells in iJ~ vitro 
models of NK cells maturation, most mnrine neonatal NK cells 
express CD94/NKG2 but not Ly49 inhibitory receptors (homo- 
logue of human KIR). The maturation stage of human neonatal 
NK cells may thus play a role in the outcome of cord blood trans- 
plantation. Some imlnunophenotypic markers are associated with 
immaturity in human in vitro models of NK ceil maturation. We 
measured, in cord blood (n= 12) and adult blood (n=12) human 
NK cells, the expression of these markers. No significant differ- 
ence was noted in the percentage of CD56brig~CD 16 'u''`/- cells, nor 
in the expression of KIRs, CD16 and CD25 between the two 
groups. As described f'or immature NK cells, CD94/NKG2A 
expression by cord blood NK cells was high (median : 79 % vs. 31 
% for adult NK cells). Immature NK cells are known to have 
fewer cytolytic granules, but 80 % of cord blood NK cells 
expressed cytoplasmic granzyme B, in contrast with adult blood 
NK ceils (9 %). XAre also compared CD28 and CD45RO expres- 
sion in the two groups. As already denaonstrated for cord blood T 
ceils, more cord blood NK cells expressed CD28 (65 % vs. 33 % 
for adult NK cells) and fewer expressed CD45RO (11% vs. 43 
%). This CD28+CD45RO- phenotype is reminiscent of that of 
naive T cells. Thus, as opposed to mouse neonatal ceils, human 
cord blood NK cells are not phenotypically immature, except br 
the expression of CD94/NKG2A. The CD28+CD45RO- pheno- 
type may indicate the absence of prior activation. Studies are 




HUMAN CYTOMEGALOVIRUS INFECTION IMPAIRS IMMUNE PHENO- 
TYPE AND FUNCTION OF IMMATURE AND MATURE MONOCYTE- 
DERIVED DENDRITIC CELLS THROUGH DISTINCT MECHANISMS 
Senechal, B.; Rea,wlz, ff.L.; Y',ml, ft.; Borz~chov, A.M.; Fore,g, ff.W. 
~Ienmvial Sloan-Ketteri77g Cance'r Center, New York, NI( 
Human cytomegalovirns (HCMV) infection is associated with 
immunosuppression. We asked whether I-:[CMV exerted direct 
effects on dendritic ells (DCs) because of their formative role in
T ceil immunity. We evaluated immature and manlre monocyte- 
derived dendritic cells (moDCs) for susceptibility to HCMV 
infection and the attendant effects on differentiation and function. 
Endothelial cell-propagated HCMV strains infected both imma- 
ture and mature moDCs, based on inmaediate early-1 fIE1) Ag 
expression. Fibroblast-propagated strains infected only mature 
moDCs. HCMV replicated much more successfully in immature 
than mature moDCs, with substantial viral particle release and cell 
lysis. HCMV infected, IEI+ gated, inanaature moDCs downregu 
iated CD83, CD86, and class I and II MItC, while expression of 
CD40 was upregaflated. IEI+ immature moDCs proved resistant, 
however, to maturation with a combination of inflammatory 
cytokines (IL 1, IL-6, TNFalpha, PGE2). IE1- gated cells from 
the same infected cultures upregulated all the above epitopes but 
expressed high levels of the inhibibtory molecule ILT3. W- inac-  
tivated HCMV could not cause comparable ffects, indicating a
requirement for viral I)NA integrity. IEI+ gated mature moDCs 
proved more resistant to HCMV-indueed down regulation of all 
epitopes except CD83. Both immature and mature infected 
moDCs exhibited impaired MLR stimulatory activity', and even 
moDCs with low rates of infection poorly stimulated the MLR. 
Transfer of virus-ftee supernatant from infected nloDCs to non- 
infected moDCs inhibited MLR stimulatory activity to the sanae 
extent as an active infection. In conclusion, HCMV infection of 
immature moDes is distinct from that of mature moDCs. Infec- 
tion of both populations impairs immune function, however, by I/ 
inhibition of maturation and downregulation of MHC and cos- 
timulatory molecules; and 2/the high expression of ILT3 on the 
bystander immature moDCs and the secretion of soluble factors 
that inhibit DC immunostimulatory function. These findings have 
important implications for immune escape by HCMV infection. 
Further studies are underway to evaluate HCMV infection of resi- 
dent populations of DCs like Langerhans cells and dermal/inter- 
stitial DCs. 
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IL-15 ADMINISTRATION AFTER ALLOGENEIC HSCT ENHANCES 
CD8+T (AND NK/T) CELL RECONSTITUTION THROUGH INCREASED 
HOMEOSTATIC PROLIFERATION WITHOUT AGGRAVATING GVHD 
Alpdogan, 0.; Mm'ighm, Sff.; EJ~g', ff.M.; l, Villis, L.M.; Tjoe, K.; 
Kirovski, A.; ~zJz Delz Brink, M.R. }Vieclidne, Memo'Hal Sloan-Kettev- 
hzg Cmzcer CeJzte'/, New York, N)~ 
Interleuldn-i5 (IL-15) is a yc cytokine, which plays an important 
role in the homeostasis of CDS+ T cells and the developnaent and 
function of natural ~ller (NIL) cells, NK T cells, and intestinal 
intraepithelial lymphocytes. We administered IL-15 (2.5 ~tg 
/day/mouse) from day 14-21 or 21-28 (in immune reconstitution 
studies) or from day 0-10 (in GVi.ID studies) in routine models 
for allogeneic hematopoietic stem cell transplantation (HSCT) to 
determine its effects on T cell reconstitution and function, and 
graft-versus-host-disease. Post-transplant IL-15 had no effect on 
overall splenic ellularity but significantly increased onor-derived 
CD8+CD122+ memory-like T cells and NK-T ceils when ana- 
lyzed at day +28 after allo tISCT. This increase in donor CD8 T 
cells was associated with increased T cell function as determined 
in a third party MLR, but did not result in auto or anti-host reac- 
tivity. We found in experinaents with the adoptive transfer of 
CFSE-labeled onor T cells that IL-l 5 could stimulate homeosta- 
tic proliferation of donor CD8 cells after a syngeneic HSCT and 
enhance the effects of IL-7 on homeostatic proliferation. IL-I5 
had a similar stimulato U effect on the homeostatic proliferation of 
non-alloreactive donor CD8 T cells after an allogeneic BMT. 
More importantly, [L-15 did not stinmlate alloreactive CD4+ or 
CD8+ T ceils and so far we have not found increased GVHD in 
two different models with CD4 or CD8 induced GVHD. In con- 
clusion, our data suggest hat IL-15 can be administered safely 
after allogeneic HSCT to specifically enhance CD8 T (and 
NK/T) ceil reconstitution and function without exacerbation of
GVHD. IL-15 seems to exert this effect primarily through the 
specific stimulation of the homeostatic proliferation of non allore- 
active donor T and NK/T cells. 
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